RANKL/RANK/OPG: key therapeutic target in bone oncology.

Ando, K., Mori, K., Rédini, F. et al. (1 more author) (2008) RANKL/RANK/OPG: key therapeutic target in bone oncology. Current Drug Discovery Technologies, 5 (3). pp. 263-268. ISSN 1570-1638



Copyright, Publisher and Additional Information: © 2008 Bentham Science Publishers KO
Keywords: Bone Neoplasms; Humans; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B
  • Published: September 2008
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 17 May 2016 12:55
Last Modified: 06 Jun 2016 17:07
Published Version: http://dx.doi.org/10.2174/157016308785739857
Status: Published
Publisher: Bentham Science Publishers
Refereed: Yes
Identification Number: https://doi.org/10.2174/157016308785739857
Related URLs:

Share / Export